



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:54
Last Report Issued 02/02/2012 08:16

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1275B
Patient ID 1275B
Chain 12000239
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 12000239
Received 02/02/2012 08:12

Sample ID 12000239-001
Matrix Blood
Patient Name 1275B
Patient ID 1275B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1275B Clonidine, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Clonidine	None Detected	ng/mL	0.10	
-----------	---------------	-------	------	--

Synonym(s): Catapres®; Duraclon; Kapvay®
Immediate-release, oral: 0.50 - 2.0 ng/mL, 2 hours after administration
Sustained-release, patch: 0.20 - 2.0 ng/mL, at steady-state
Sustained-release, oral: 0.20 - 0.27 ng/mL, 6.8 +/- 3.6 hours after a 0.1 mg single dose in healthy fed adults;
children receive higher doses on a mg/kg basis.

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.